Sec. 40. Prospective DUR must be based on the guidelines established by the board and must provide that prior to the prescription being filled or delivered a review will be conducted by the pharmacist at the point of sale to screen for potential drug therapy problems resulting from the following:

(1) Therapeutic duplication.

Ask a legal question, get an answer ASAP!
Click here to chat with a lawyer about your rights.

Terms Used In Indiana Code 12-15-35-40

  • board: refers to the drug utilization review board created under this chapter. See Indiana Code 12-15-35-2
  • DUR: means the program designed to measure and assess on a retrospective and a prospective basis the proper use of outpatient drugs in the Medicaid program. See Indiana Code 12-15-35-8
  • pharmacist: means an individual who is licensed as a pharmacist in Indiana under IC 25-26. See Indiana Code 12-15-35-11
(2) Drug-drug interactions.

(3) Incorrect dosage and duration of treatment.

(4) Drug-allergy interactions.

(5) Clinical abuse and misuse.

As added by P.L.75-1992, SEC.19.